Article

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Howard Hughes Medical Institute, Portland, Oregon 97239, USA.
Cancer Cell (Impact Factor: 23.89). 08/2006; 10(1):65-75. DOI: 10.1016/j.ccr.2006.06.002
Source: PubMed

ABSTRACT Tyrosine kinases are aberrantly activated in numerous malignancies, including acute myeloid leukemia (AML). To identify tyrosine kinases activated in AML, we developed a screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry. This allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK. Subsequent analysis identified two additional JAK3 alleles, V722I and P132T, in AMKL patients. JAK3(A572V), JAK3(V722I), and JAK3(P132T) each transform Ba/F3 cells to factor-independent growth, and JAK3(A572V) confers features of megakaryoblastic leukemia in a murine model. These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations.

0 Bookmarks
 · 
173 Views

Full-text (2 Sources)

Download
142 Downloads
Available from
May 29, 2014